AI-Driven Antibody Discovery Services

Are you currently facing prolonged antibody development cycles and challenges in identifying novel, high-potential therapeutic candidates? Our AI-Driven One-stop Antibody Discovery Platform helps you accelerate the birth of new antibody molecules with ideal properties and streamline candidate identification through advanced generative AI models and high-throughput computational screening, breaking through traditional limitations.

The Challenge in Traditional Antibody Discovery

The pathway from target identification to market-ready antibody therapeutics is notoriously complex, lengthy, and resource-heavy, with traditional methods hindered by the diversity of starting materials and experimental scale. At Creative Biolabs, we utilize Artificial Intelligence to transform antibody discovery, moving beyond optimization to AI-driven generation of innovative antibody sequences from new perspectives, harnessing AI's creative and recognition capabilities to explore a broader, more diverse space.

One-stop AI Antibody Discovery

Creative Biolabs offers AI antibody discovery services centered on AI-driven novel antibody sequence generation and the early identification of promising candidate molecules. This service seeks to transcend the constraints of traditional antibody discovery methods via cutting-edge AI technology, expediting the creation of new antibodies with optimal properties. Our methodology involves de novo generate antibody sequence and using AI to model protein dynamics, thereby expediting discovery. The resulting antibody sequences are carefully crafted to enhance therapeutic efficacy while minimizing safety and manufacturing risks.

Fig.1 Classical and AI-Driven de novo Discovery Pipelines.¹

Antibody Discovery Services

• AI-Driven De Novo Antibody Sequence Generation

Advanced generative AI models enable the creation of novel and diverse antibody amino acid sequences tailored to given target structures, sequences, or functional needs, ensuring optimal binding characteristics, stability, and pharmaceutical properties.

• AI-Driven Protein Motion Simulation Service

Leveraging AI, we simulate protein dynamics to hasten drug discovery, predicting atomic-level antibody-target interactions. This virtual screening method quickly identifies lead candidates, reducing reliance on wet-lab experiments and streamlining the drug development process.

Why Choose Us?

Artificial intelligence (AI) technologies have also been widely used in antibody design based on big data and machine learning. In addition, the biophysical features of candidate antibodies, such as stability, solubility, chemical properties can be evaluated and optimized by different types of AI models to reduce the cost and improve the therapeutic efficiency.

• AI can typically generate 10 times more antibody sequence clusters than a laboratory-based approach alone.
• Antibody diversity expanded by AI leads to the discovery of new binding modalities and potentially new therapeutic modes-of-action.

Creative Biolabs is recognized as the world leader for providing the most diverse portfolio of AI-augmented drug discovery solutions for worldwide customers. We are proud to partner with our clients on the journey of bringing novel antibody candidates to market. If you are interested in our services, please feel free to contact us for closer communication.

Reference

1. Musnier, Astrid, et al. "Applying artificial intelligence to accelerate and de-risk antibody discovery." Frontiers in Drug Discovery 4 (2024): 1339697. Distributed under Open Access license CC BY 4.0, without modification.